Considering the dual role of NF-κB in inducing an antitumor immune response against cancerous cells, and inducing the expression of immune checkpoints in Treg cells, employment of NF-κB suppressors for cancer immunotherapy is challenging [143, 144]. This evidence concerns the gene NFKB1 and cancer.